In addition to breast cancer, CDK5 mRNA expression is important in other tumour types; in blood cancers, low CDK5 mRNA expression has been shown to be associated with adverse survival (n = 53) and high CDK5 expression has been associated with shorter overall survival in lung cancer.10 Here, CDK5 is linked to hematopoietic and lymphoid system neoplasm.